See more : Nanoco Group plc (NNOCF) Income Statement Analysis – Financial Results
Complete financial analysis of Adjuvant Holdings Co.,Ltd. (4929.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Adjuvant Holdings Co.,Ltd., a leading company in the Household & Personal Products industry within the Consumer Defensive sector.
You may be interested
- Edgio, Inc. (0JUZ.L) Income Statement Analysis – Financial Results
- SHO-BOND Holdings Co.,Ltd. (1414.T) Income Statement Analysis – Financial Results
- Boart Longyear Group Ltd. (BLYFF) Income Statement Analysis – Financial Results
- ARIAKE JAPAN Co., Ltd. (AKEJF) Income Statement Analysis – Financial Results
- RTL Group S.A. (RRTL.DE) Income Statement Analysis – Financial Results
Adjuvant Holdings Co.,Ltd. (4929.T)
Industry: Household & Personal Products
Sector: Consumer Defensive
Website: https://www.adjuvant.co.jp
About Adjuvant Holdings Co.,Ltd.
Adjuvant Holdings Co.,Ltd. engages in the research, development, production, and sale of cosmetics in Japan. The company offers skin care products, including cleansing products, face washes, lotions, beauty essences, masks, moisturizing creams, makeup bases, makeups, and body care products; hair care products comprising shampoos, treatments, scalp cleansing products, scalp lotions, and styling products; and other products. It serves hairdressing salons, barber shops, and esthetic salons. The company was formerly known as Adjuvant Cosme Japan Co.,Ltd. and changed its name to Adjuvant Holdings Co.,Ltd. in September 2021. Adjuvant Holdings Co.,Ltd. was founded in 1990 and is headquartered in Kobe, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.44B | 4.38B | 4.43B | 4.89B | 4.67B | 5.16B | 5.10B | 4.77B | 4.40B | 4.50B | 4.57B | 4.47B | 4.14B |
| Cost of Revenue | 1.58B | 1.46B | 1.49B | 1.89B | 1.86B | 2.00B | 1.90B | 1.76B | 1.59B | 1.63B | 1.58B | 1.59B | 1.41B |
| Gross Profit | 2.86B | 2.92B | 2.94B | 3.00B | 2.81B | 3.16B | 3.20B | 3.01B | 2.81B | 2.87B | 2.99B | 2.88B | 2.73B |
| Gross Profit Ratio | 64.45% | 66.61% | 66.45% | 61.35% | 60.12% | 61.23% | 62.80% | 63.07% | 63.82% | 63.73% | 65.41% | 64.36% | 65.98% |
| Research & Development | 179.83M | 181.00M | 173.00M | 151.00M | 161.00M | 146.00M | 156.69M | 142.42M | 110.53M | 54.00M | 43.00M | 36.00M | 0.00 |
| General & Administrative | 182.00M | 167.00M | 164.00M | 242.00M | 248.00M | 220.00M | 241.00M | 221.00M | 176.00M | 179.00M | 179.00M | 192.00M | 0.00 |
| Selling & Marketing | 574.00M | 306.00M | 232.00M | 253.00M | 401.00M | 428.00M | 369.00M | 373.00M | 346.00M | 376.00M | 396.00M | 365.00M | 0.00 |
| SG&A | 2.68B | 2.68B | 2.55B | 2.70B | 3.00B | 2.99B | 2.54B | 2.35B | 2.05B | 2.14B | 1.99B | 1.89B | 0.00 |
| Other Expenses | 0.00 | 7.08M | -9.06M | 22.84M | 8.17M | 72.80M | 8.34M | 7.94M | 66.87M | 1.74M | -578.00K | -12.16M | 16.27M |
| Operating Expenses | 2.86B | 2.68B | 2.55B | 2.70B | 2.99B | 2.99B | 2.70B | 2.49B | 2.16B | 2.14B | 1.99B | 1.89B | 1.80B |
| Cost & Expenses | 4.44B | 4.14B | 4.04B | 4.59B | 4.86B | 4.99B | 4.60B | 4.25B | 3.75B | 3.77B | 3.57B | 3.48B | 3.21B |
| Interest Income | 1.08M | 1.28M | 3.85M | 3.90M | 3.82M | 6.21M | 5.18M | 3.84M | 3.46M | 2.24M | 1.52M | 322.00K | 231.00K |
| Interest Expense | 0.00 | 0.00 | 3.85M | 40.00K | 101.00K | 191.00K | 470.00K | 880.00K | 43.00K | 0.00 | 2.04M | 11.08M | 12.79M |
| Depreciation & Amortization | 125.41M | 108.85M | 110.43M | 110.64M | 117.60M | 98.86M | 97.28M | 95.37M | 77.69M | 84.63M | 81.95M | 76.61M | 80.18M |
| EBITDA | 124.00M | 697.06M | 500.79M | 292.22M | -44.61M | 282.07M | 608.54M | 634.89M | 671.79M | 1.18B | 1.09B | 1.06B | 994.66M |
| EBITDA Ratio | 2.79% | 0.42% | 10.44% | 8.92% | -0.66% | 6.79% | 11.90% | 13.09% | 17.91% | 23.09% | 23.89% | 23.79% | 25.06% |
| Operating Income | -1.43M | 232.69M | 390.36M | 292.93M | -184.62M | 169.79M | 500.46M | 519.06M | 647.03M | 733.90M | 1.00B | 988.65M | 938.92M |
| Operating Income Ratio | -0.03% | 5.32% | 8.82% | 6.00% | -3.95% | 3.29% | 9.82% | 10.88% | 14.70% | 16.30% | 21.92% | 22.12% | 22.65% |
| Total Other Income/Expenses | 16.72M | 355.53M | 49.18M | -111.40M | 22.31M | 13.24M | 10.34M | 19.59M | -52.97M | -195.75M | 1.09M | -13.45M | -37.21M |
| Income Before Tax | 15.30M | 588.21M | 439.54M | 181.53M | -162.30M | 183.02M | 510.79M | 538.64M | 594.06M | 538.25M | 1.00B | 975.21M | 901.70M |
| Income Before Tax Ratio | 0.34% | 13.44% | 9.93% | 3.72% | -3.47% | 3.54% | 10.02% | 11.29% | 13.50% | 11.95% | 21.95% | 21.82% | 21.75% |
| Income Tax Expense | 115.16M | 184.57M | 46.36M | 39.15M | 65.62M | 157.96M | 199.77M | 208.11M | 327.96M | 491.21M | 431.44M | 441.92M | 625.45M |
| Net Income | -99.87M | 403.64M | 393.18M | 142.38M | -227.93M | 25.06M | 311.02M | 330.54M | 266.10M | 47.04M | 571.73M | 533.29M | 276.25M |
| Net Income Ratio | -2.25% | 9.22% | 8.88% | 2.91% | -4.88% | 0.49% | 6.10% | 6.93% | 6.05% | 1.04% | 12.51% | 11.93% | 6.66% |
| EPS | -12.49 | 50.46 | 49.13 | 17.83 | -28.63 | 3.16 | 39.32 | 41.72 | 33.83 | 6.08 | 76.10 | 85.92 | 51.34 |
| EPS Diluted | -12.49 | 50.46 | 49.08 | 17.76 | -28.63 | 3.14 | 39.09 | 41.49 | 33.44 | 5.96 | 73.81 | 82.12 | 51.34 |
| Weighted Avg Shares Out | 8.00M | 8.00M | 8.00M | 7.99M | 7.96M | 7.94M | 7.91M | 7.92M | 7.87M | 7.73M | 7.51M | 6.21M | 5.38M |
| Weighted Avg Shares Out (Dil) | 8.00M | 8.00M | 8.01M | 8.02M | 7.96M | 7.98M | 7.96M | 7.97M | 7.96M | 7.89M | 7.75M | 6.49M | 5.38M |
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
Study done in collaboration with Memorial Sloan Kettering and led by Dr. Winston Wong, Head and Neck Oncologist and Dr. Alan Ho, Chief of the Head and Neck Oncology Service
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--U.S. FDA Approves Perioperative Treatment of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo.
Astellas Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy
- HIGHLIGHT 1™ study to evaluate fezolinetant for treatment of moderate to severe vasomotor symptoms in women with stage 0-3 hormone receptor positive breast cancer receiving adjuvant endocrine therapy - TOKYO , Aug. 27, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503,...
New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced the publication of a study demonstrating the impact of the DecisionDx-SCC test in guiding adjuvant radiation therapy decision-making.
Devoir de vigilance : TotalEnergies regrette le refus par les ONG de la médiation proposée par le Tribunal judiciaire de Paris
PARIS--(BUSINESS WIRE)--Regulatory News: Alors que s’est tenue aujourd’hui une audience devant le juge des référés du tribunal judiciaire de Paris, TotalEnergies (Paris:TTE) (LSE:TTE) (NYSE:TTE) regrette que les ONG engagées dans la procédure aient refusé la médiation proposée par le tribunal,...
Safety Management Group To Exhibit At The NSC Safety Congress & Expo
INDIANAPOLIS--(BUSINESS WIRE)--Safety Management Group (SMG), an industry-leading safety, environmental and quality services firm, today announced that the company will exhibit in booth #4929 at the NSC Safety Congress & Expo on Sept. 19 - 21, 2022. Demos of SMG’s VERO...
Berkshire Hathaway Specialty Insurance Promotes Two Casualty Leaders in the UK
BOSTON & LONDON--(BUSINESS WIRE)--Berkshire Hathaway Specialty Insurance (BHSI) today announced that it has promoted Caroline Alder-Smurthwaite to Head of Casualty and James Emson to the role of Head of Technical Casualty in the UK. “Caroline and James are committed to...
Dr. Deborah Gross Answers the Call
BIRMINGHAM, Ala.--(BUSINESS WIRE)--Pathway Healthcare is excited to announce that Dr. Deborah Gross is now licensed to practice in all four states Pathway Healthcare has office locations. Dr. Gross can treat patients in the states of Alabama, Mississippi, Tennessee, and Texas....
Fidelity® Study: More Than 4 in 10 Working Caregivers May Be Forced to Choose Between Their Job and Caregiving in the Coming Year
BOSTON--(BUSINESS WIRE)--With school back in session and the holidays fast approaching, caregivers are viewing this latest stage of the pandemic with a mixture of anxiety and optimism, according to new data from Fidelity Investments® latest American Caregivers study. While 68%...
Pathway Healthcare’s Winter Storm Response
BIRMINGHAM, Ala.--(BUSINESS WIRE)--Pathway Healthcare (www.pathwayhealthcare.com). The winter storms which ravaged the southern states in late February 2021 not only closed roads and schools, it also created an emergency situation for those being treated for addiction and mental health. “Our patients...
Source: https://incomestatements.info
Category: Stock Reports